TB-500 Peptide: What Is It Studied For?

What Is TB-500?

TB-500 is a synthetic peptide corresponding to the amino acid sequence LKKTETQ — the active actin-binding region of the naturally occurring protein Thymosin Beta-4 (Tβ4). That distinction matters: TB-500 is a fragment, not the full-length protein. Much of the published biological literature examines full-length Tβ4, and findings from those studies cannot be attributed directly to TB-500 without stating the difference. The compound emerged in veterinary contexts as an injectable preparation and has since drawn attention from doping control researchers, wound-healing scientists, and neuroscience laboratories. Its N-terminus carries an artificial acetyl group (Ac-LKKTETQ), a modification confirmed in equine doping studies as the key structural feature of commercially circulating TB-500 preparations.

---

What Is TB-500 Studied For?

Research on TB-500 goes back to 2013 — nearly 10 years — with studies continuing through 2026.

1. Wound Healing and Tissue Repair — A 2024 in vitro and rodent preclinical study published in the Journal of Chromatography B quantified TB-500 and its metabolites simultaneously, reporting that both the parent compound (Ac-LKKTETQ) and its unacetylated form demonstrated wound-healing activity in cell-based scratch assays, with the unacetylated metabolite showing measurable activity as well.

2. Corneal Injury Repair — A 2025 preclinical study in ACS Applied Materials & Interfaces incorporated TB-500 into an alkaline phosphatase-triggered peptide hydrogel and tested it in animal corneal wound models, reporting spatiotemporal repair of corneal tissue through a lesion-responsive delivery mechanism.

3. Neuroinflammation and Cognitive Decline — A 2026 preclinical study in International Immunopharmacology tested TB-500 and a related Tβ4 derivative (Ac-SDKP) in both in vitro Alzheimer's disease (AD) cell systems and 5×FAD transgenic mice, reporting reductions in neuroinflammation and neurite atrophy alongside preliminary memory-related outcomes in the mouse model.

4. Anti-Doping Detection (Equine and Human Matrices) — A 2013 preclinical analytical study in the Journal of Chromatography A developed the first liquid chromatography-mass spectrometry (LC-MS) method for detecting TB-500 in equine urine and plasma, establishing the compound's pharmacokinetic traceability and confirming its identity in veterinary commercial preparations.

5. Human Doping Surveillance — A 2022 study of unclear design in the Journal of Chromatography A developed a multi-analyte screening assay for small peptides including TB-500 in human biological samples, representing the primary published intersection of TB-500 with human-matrix analytical work — though the study was analytical in nature, not a clinical efficacy trial, and reported no sample size for human subjects tested.

---

How Does TB-500 Work?

TB-500's biological activity centers on its capacity to bind G-actin — the monomeric form of actin that drives cytoskeletal dynamics in cells. The sequence LKKTETQ corresponds to the WH2 domain within Thymosin Beta-4 that governs this interaction. By sequestering G-actin, the peptide modulates polymerization and affects downstream processes including cell migration, proliferation, and angiogenesis.

The 2024 UHPLC-Q-Exactive Orbitrap MS/MS study traced TB-500's metabolic fate in rats and in vitro systems, finding that the compound is cleaved into smaller fragments after administration. Notably, the unacetylated form LKKTETQ — generated during metabolism — retained wound-healing activity in cell-based models. This suggests that the biological signal may persist beyond the intact parent molecule, though the relative contributions of each fragment have not been fully characterized.

The 2025 hydrogel study added a delivery-mechanism dimension: researchers embedded TB-500 in a scaffold triggered by alkaline phosphatase, an enzyme upregulated at corneal injury sites. The rationale was that localized enzyme activity would release the peptide precisely where tissue disruption had occurred, extending its effective residence time at the wound site.

---

What Does Animal Research Show?

The bulk of published TB-500 research uses animal or in vitro models. Three studies are particularly informative about tissue-level outcomes.

The 2024 rodent and in vitro study provided the most granular pharmacological characterization to date. Using UHPLC-Q-Exactive Orbitrap mass spectrometry, researchers simultaneously quantified TB-500 and seven metabolites in rat samples and cell culture media. Wound-healing activity was confirmed through scratch assay data for both the acetylated parent and the LKKTETQ fragment, though the study did not report dose-response comparisons in intact animals beyond pharmacokinetic profiling.

The 2025 corneal study in ACS Applied Materials & Interfaces operated at a tissue-engineering level. The ALP-responsive hydrogel delivered TB-500 in a spatially controlled fashion to animal corneal wounds, and the preclinical data showed measurable improvement in tissue repair metrics. The study is notable for being among the first to address TB-500's practical limitation — rapid clearance from topical or injection sites — through an engineered delivery scaffold, though sample sizes were not reported in the available abstract.

The 2026 International Immunopharmacology study used the 5×FAD mouse model, which carries five familial Alzheimer's disease mutations, to evaluate whether TB-500 and Ac-SDKP could counter AD-related neuropathology. Both in vitro (AD cell systems) and in vivo (transgenic mice) findings pointed toward reduced neuroinflammation and preserved neurite architecture. Because this study examined both TB-500 and the co-administered Ac-SDKP, the independent contribution of each compound remains difficult to isolate from the published data.

---

What Does Human Research Show?

No published clinical trial has evaluated TB-500's efficacy or safety in human subjects. The human-matrix data that does exist comes entirely from analytical and doping-control research, not therapeutic investigation.

The 2013 equine doping study in the Journal of Chromatography A established LC-MS detection methods in horse plasma and urine, providing pharmacokinetic reference data for the intact peptide and its fragments. That same journal published a 2022 multi-analyte screening study — of unclear participant design and unreported sample size — that extended small-peptide detection methodology to human biological matrices. Both studies were designed to identify and quantify the compound, not to assess any clinical outcome.

TB-500's presence on the World Anti-Doping Agency (WADA) prohibited list reflects regulatory concern about its use in competitive sports, a point made explicitly in the 2022 screening paper. The 2013 veterinary doping analysis also noted that commercial preparations were circulating without regulatory approval from the EMA or FDA — a point reinforced in a separate 2023 study in Drug Testing and Analysis that characterized TB-500 products alongside misbranded veterinary formulations (TB1000, SGF1000), finding inconsistencies in labeled versus actual composition.

It bears repeating: no results from Tβ4 human studies transfer automatically to TB-500. The structural overlap is real, but the fragment and the full-length protein are pharmacologically distinct entities, and clinical data on one cannot be cited as evidence for the other.

---

What Is Still Unknown About TB-500?

Several gaps limit what can be concluded from the existing literature.

First, the metabolic findings from the 2024 rodent study — showing that LKKTETQ retains wound-healing activity — raise a basic pharmacological question: is the intact Ac-LKKTETQ necessary for the observed effects, or does the compound function mainly as a prodrug that releases the unacetylated fragment? That question has not been answered in any published study.

Second, all tissue-repair and neuroprotective findings come from animal or cell-based models. The translation of those findings to human physiology remains uninvestigated. The corneal hydrogel system, for example, has not been tested beyond preclinical stages.

Third, the 2023 Drug Testing and Analysis study flagged commercial TB-500 products for composition inconsistencies, including adulteration and mislabeling. This creates a compounding uncertainty: even if future clinical research establishes a defined pharmacological profile for TB-500, product purity in the research supply chain would need to be independently confirmed for any data to be interpretable.

Fourth, the role of the N-terminal acetyl group is incompletely characterized. The 2013 equine doping study confirmed that the acetylated form is the key commercial ingredient and is detectable by LC-MS, but comparative biological data between the acetylated and unacetylated forms in intact animal systems remains limited to the 2024 in vitro scratch assay data.

Research is continuing: the emergence of delivery-engineering approaches (the 2025 hydrogel study) and neurological indications (the 2026 AD study) indicate that the field is broadening beyond wound healing and sports doping surveillance. Whether that expands into human trials depends on data that has not yet been published.

---

Where Can I Buy TB-500?

TB-500 is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---